S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Silence Therapeutics Stock Forecast, Price & News

+0.15 (+1.27%)
(As of 07/1/2022 03:58 PM ET)
Today's Range
50-Day Range
52-Week Range
4,725 shs
Average Volume
35,508 shs
Market Capitalization
$359.16 million
P/E Ratio
Dividend Yield
Price Target

Silence Therapeutics MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
433.3% Upside
$64.00 Price Target
Short Interest
0.06% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($2.24) to ($2.03) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.94 out of 5 stars

Medical Sector

579th out of 1,428 stocks

Pharmaceutical Preparations Industry

277th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Silence Therapeutics logo

About Silence Therapeutics (NASDAQ:SLN) Stock

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

SLN Stock News Headlines

Simple Strategies to Profit in This Market
Learn strategies for how to make money no matter the market direction. Save your seat at our FREE, LIVE online class. Find out how to navigate volatility and choppy markets.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$17.07 million
Book Value
$0.39 per share


Free Float
Market Cap
$359.16 million
Not Optionable

Silence Therapeutics Frequently Asked Questions

Should I buy or sell Silence Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Silence Therapeutics stock.
View analyst ratings for Silence Therapeutics
or view top-rated stocks.

What is Silence Therapeutics' stock price forecast for 2022?

3 Wall Street research analysts have issued 12-month target prices for Silence Therapeutics' stock. Their SLN stock forecasts range from $33.00 to $95.00. On average, they predict Silence Therapeutics' share price to reach $64.00 in the next twelve months. This suggests a possible upside of 433.3% from the stock's current price.
View analysts' price targets for Silence Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Silence Therapeutics' stock performed in 2022?

Silence Therapeutics' stock was trading at $23.89 at the beginning of 2022. Since then, SLN stock has decreased by 49.8% and is now trading at $12.00.
View the best growth stocks for 2022 here

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (NASDAQ:SLN) issued its quarterly earnings data on Monday, May, 16th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.27. The company earned $7.68 million during the quarter.
View Silence Therapeutics' earnings history

Who are Silence Therapeutics' key executives?

Silence Therapeutics' management team includes the following people:
  • Mr. Craig A. Tooman M.B.A., MBA, Pres, CEO & Director (Age 56, Pay $479.16k)
  • Ms. Rhonda L. Hellums, Chief Financial Officer (Age 50, Pay $268.8k)
  • Dr. Giles V. Campion M.D., Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director (Age 68, Pay $614.93k)
  • Ms. Gem Gokmen Hopkins, Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin, Sr. VP, Gen. Counsel & Chief Patent Officer (Age 62)
  • Mr. Eric Fink, Chief HR Officer (Age 44)
  • Dr. John Strafford Ph.D., Sr. VP of Bus. Devel., Alliance Management & New Product Devel.
  • Mr. Jørgen Wittendorff, Sr. VP & Head of Manufacturing
  • Dr. Eric Floyd Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance (Age 60)
  • Dr. Marie Wikstrom Lindholm Ph.D., Sr. VP & Head of Molecular Design

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the NASDAQ under the ticker symbol "SLN."

How do I buy shares of Silence Therapeutics?

Shares of SLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately $12.00.

How much money does Silence Therapeutics make?

Silence Therapeutics (NASDAQ:SLN) has a market capitalization of $359.16 million and generates $17.07 million in revenue each year.

How many employees does Silence Therapeutics have?

Silence Therapeutics employs 105 workers across the globe.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The official website for Silence Therapeutics is www.silence-therapeutics.com. The company can be reached via phone at 44-0-20-3457-6900.

This page (NASDAQ:SLN) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.